Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In multivariate analysis, ERCC-1 expression, T-stage, N-stage and tumor subsite are predictive factors for LRF; T-stage and nodal recurrence for OS; stage and treatment response for PFS.
|
31612639 |
2020 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ERCC1 gene expression is significantly related to tumor stage and prognosis in resected ESCC patients from Asian countries.
|
31713119 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
First-line FOLFIRI-BV and mFOLFOX6-BV had comparable PFS and OS, similar to results in patients with high baseline tumor ERCC1 levels.
|
30224341 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
|
30589644 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High ERCC1 expression was found in 47.3% patients, and was correlated with higher TNM (p = 0.021), tumor enlargement (p = 0.002), positive lymph nodes (p = 0.001), positive distant metastasis (p = 0.005), and higher relative risk of death (p < 0.001).
|
31521181 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, low ERCC1/low XPF (p = 0.003) or low ERCC1/low PARP1 (p = 0.0001) tumors was also linked to better PFS compared to high ERCC1/high XPF or high ERCC1/high PARP1 tumors.
|
30797591 |
2019 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Higher rates of low ERCC1 (35.6 vs. 20.3%, P = 0.0105), RRM1 (23.3 vs. 13.0%, P = 0.0437), STMN1 (72.2 vs. 42.8%, P = 0.0000) and high VEGFR2 (34.4 vs. 18.8%, P = 0.0078) mRNA expression were found in EGFR-mutated tumors, suggesting possible benefit from platinum, gemcitabine, taxanes or VEGFR2 inhibitors.
|
29948972 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While enhanced sPD-L1 was associated with residual tumor burden (<i>p</i> = 0.022), reduced sPD-L2 levels were related to platinum-resistance (<i>p</i> < 0.01) and the presence of ERCC1+ CTCs (<i>p</i> < 0.0001).
|
31681568 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We retrospectively analyzed tumor tissue of 72 patients using immunohistochemistry to assess the expression of ERCC1.
|
29905882 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggest that two or three negative expressions of p53, p53R2, and ERCC1 in biopsy specimens of primary tumors were associated with a favorable response to CRT for ESCC.
|
29188501 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings provided evidence that both blood and tumor tissue MGMT and ERCC1 methylation were associated with cancer rectum.
|
29080834 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis data revealed that ERCC1 and survivin protein expression were independent predictors of overall survival of ESCC patients after chemotherapy and/or radiotherapy (P < .05).ERCC1 overexpression is an important phenotype that is associated with ESCC lymph node metastasis and advanced tumor clinical stages.
|
30075571 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We hypothesized that ERCC1 expression and tumour infiltrating lymphocytes (TILS) are induced by chemotherapy in HGSOC, which may be prognostically useful.
|
30194007 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
|
28388557 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results of the present study suggest that ERCC1 expression is an important prognostic indicator for NSCLC, particularly for patients with stage II-III tumors who receive systematic platinum-based adjuvant chemotherapy.
|
28927101 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High ERCC1 expression was strongly associated with the presence of genomic alterations and expression levels increased with the number of deletions present in the tumor.
|
28747165 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin.
|
28259288 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In multivariate analysis performance status (PS), stage of the disease and ERCC1-mRNA expression were independent prognostic factors for EFS whereas tumor histology and stage of the disease were independent factors for OS.
|
28088319 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A multivariate logistic regression analysis indicated that pathological responses were significantly associated with tumors with low ERCC1 expression (P = 0.016) and with tumors with high BRCA1 expression (P = 0.030).
|
27130464 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High expression of ERCC1 was observed in 33 cases (14.7%) and was statistically associated with lower T stage (P=0.005), lower tumor size (P=0.001), no lymph node metastasis (P=0.044) and no lymphovascular invasion (LVI; P=0.004).
|
28943968 |
2017 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus, pretreatment ERCC1 expression status can be used to predict tumor response and survival of patients with recurrent or metastatic uterine cervical cancer receiving platinum-based chemotherapy.
|
29390553 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The relative mRNA levels of seven genes including ERBB2, MET, VEGFA, EREG, AREG, PTEN and ERCC1 between tumour (T) and non-tumour (NT) tissue sections were analysed by quantitative real-time PCR.
|
27002940 |
2016 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ERCC1 expression, evaluated by techniques such as immunohistochemistry, has been associated with clinical response; ERCC1<sup>+</sup> tumors are more resistant to cisplatin treatment than are ERCC1<sup>-</sup> tumors.
|
27610644 |
2016 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The ERCC1 expression state did not significantly vary between patient groups according to sex, age, primary tumor site, and tumor and node stage.
|
27165214 |
2016 |